mRNA Vaccines Could Revolutionize Cancer Treatment Here’s a look at the status of mRNA technology's application in cancer and when it might reach patients. Inverse · Jun 18, 2023
Ukraine, Sudan conflicts fuel alarming surge in tuberculosis Top U.N. officials and health industry leaders are trying to tackle an alarming surge in tuberculosis, which is now killing more people worldwide than COVID-19 or AIDS The Independent UK · May 8, 2023
Pfizer, BioNTech Propose EU Pays Half for Each Cancelled COVID Dose Pfizer Inc and BioNTech's new proposal to the European Union, amid a glut of COVID-19 shots, includes a provision for member states to pay half price, or about 10 euros ($11), for each of about 70 million cancelled doses, the Financial Times reported on Sunday. The revised contract would allow… Asharq Al-Awsat · Apr 30, 2023
‘Groundbreaking’ cancer and heart disease vaccine ‘could save millions of lives’ Experts hope new vaccines will be ready by end of decade The Independent UK · Apr 8, 2023
‘A silver lining’: how Covid ushered in a vaccines golden era Pandemic accelerated advances in vaccine technology, opening up possibilities for combating array of diseases The Guardian - UK · Apr 7, 2023
Rwanda welcomes Africa's first mobile vaccine-production units Six mobile vaccine-production units developed by German pharmaceutical company BioNTech have arrived in Rwanda. This is the first such shipment to Africa as the continent seeks to boost local production of mRNA vaccines. Radio France Internationale · Mar 14, 2023
What are these 'cancer vaccines' I'm hearing about? And what similarities do they share with COVID vaccines? Barely a month goes by without headlines announcing yet another advancement in cancer vaccines. The Conversation · Mar 6, 2023
What are these ‘cancer vaccines’ making news? Are there similarities with COVID vaccines? Using the same mRNA technology as COVID vaccines, cancer vaccines are an emerging personalised treatment for cancer. The New Daily · Mar 6, 2023
Moderna, Pfizer and BioNTech Covid vaccine patent dispute heads to 2024 trial US firm Moderna is suing its competitors for alleged patent infringement in relation to their Comirnaty vaccine. The Independent UK · Feb 16, 2023
In synthetic biology, startups and incumbent companies should be partners, not foes In this crucial area of innovation, established companies and startups must work together to deliver the benefits that the science promises. Fortune · Feb 3, 2023
‘This will happen before 2030’: how the science behind Covid vaccines might help to fight cancer The success of mRNA-based drugs in combating coronavirus is inspiring scientists to create similar vaccines for melanoma and other tumours The Guardian - UK · Jan 22, 2023
At buzzy health care business conference, investors fear the bubble will burst JPMorgan's cheery confab returned to San Francisco, but the health care capitalists had economic anxiety, too. WEKU · Jan 20, 2023
Health care investors convene in SF Health care’s business class returned to San Francisco last week for JPMorgan’s annual health care confab Salon · Jan 17, 2023
Mainlanders seek mRNA vaccines in Hong Kong HONG KONG: Scores of mainland Chinese travellers are rushing to Hong Kong to receive mRNA Covid-19 vaccines, which are not available on the Chinese mainland, as the country grapples with a torrent of infections that have overwhelmed its health system. Bangkok Post · Jan 12, 2023
Reuters · Jan 12, 2023 Mainland Chinese head to Hong Kong for mRNA COVID vaccines Scores of mainland Chinese travellers are rushing to Hong Kong to receive mRNA COVID-19 vaccines, which are not available on the Chinese mainland, as the country grapples with a torrent of infections which have overwhelmed its health system.
The Conversation · Jan 12, 2023 Cancer vaccine trials could start in the autumn – UK signs deal with BioNTech The UK government recently announced that it is partnering with German firm BioNTech to test vaccines for cancer and other diseases. The project aims to build on the mRNA vaccine technology that BioNTech became famous for developing, and which has been so successful at preventing serious illness and death from…
ABC News · Jan 7, 2023 Plan for mRNA cancer vaccine trials to start in United Kingdom this year Personalised cancer vaccine trials in England will roll out this year after the United Kingdom government signed a deal with a company behind one of the major COVID-19 vaccines.
Caixin Global · Jan 6, 2023 Chinese Mainlanders Can Book Omicron-Specific mRNA Shot in Hong Kong Fosun Pharma opens online reservation platform for BioNTech vaccination as Covid border controls are set to end
Evening Standard · Jan 6, 2023 UK signs groundbreaking mRNA cancer vaccine research agreement The partnership with German pharmaceutical company BioNTech will be one of the first of its kind
The Independent UK · Jan 6, 2023 UK speeds up plans to develop mRNA vaccines for cancer patients with BioNTech deal Deal follows UK’s largely successful Covid vaccine roll out
The Guardian - UK · Jan 6, 2023 Cancer vaccine trials could start in England by autumn Government deal with BioNTech paves way for early access to trials of personalised mRNA therapies
Reuters · Jan 6, 2023 BioNTech signs deal with UK for personalised cancer therapies BioNTech SE has signed a deal with the UK government to enrol up to 10,000 patients in clinical trials by the end of 2030 for personalised cancer therapies, the German drug maker said.
Wales Online · Jan 6, 2023 UK Health Secretary to sign cancer treatments deal for patients in England Steve Barclay is set to sign a memorandum of understanding with BioNTech to ensure high quality cancer treatments are available as soon as possible
The Independent UK · Jan 6, 2023 Health Secretary to sign cancer treatments deal with leading pharmaceutical company Steve Barclay is due to sign a memorandum of understanding with BioNTech on Friday.
Inverse · Jan 5, 2023 Here are the 5 biggest innovations to expect in 2023 Inverse predicts the biggest innovations of 2023, including wins in renewable energy, electric vehicles, and biotechnology.